These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 14978071)

  • 21. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand.
    Nagase H; Okugawa S; Ota Y; Yamaguchi M; Tomizawa H; Matsushima K; Ohta K; Yamamoto K; Hirai K
    J Immunol; 2003 Oct; 171(8):3977-82. PubMed ID: 14530316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Toll-like receptors and immune response in allergic disease.
    Gangloff SC; Guenounou M
    Clin Rev Allergy Immunol; 2004 Apr; 26(2):115-25. PubMed ID: 15146108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel role for IL-3: human monocytes cultured in the presence of IL-3 and IL-4 differentiate into dendritic cells that produce less IL-12 and shift Th cell responses toward a Th2 cytokine pattern.
    Ebner S; Hofer S; Nguyen VA; Fürhapter C; Herold M; Fritsch P; Heufler C; Romani N
    J Immunol; 2002 Jun; 168(12):6199-207. PubMed ID: 12055233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
    Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
    Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Injury primes the innate immune system for enhanced Toll-like receptor reactivity.
    Paterson HM; Murphy TJ; Purcell EJ; Shelley O; Kriynovich SJ; Lien E; Mannick JA; Lederer JA
    J Immunol; 2003 Aug; 171(3):1473-83. PubMed ID: 12874240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells.
    Re F; Strominger JL
    J Immunol; 2004 Dec; 173(12):7548-55. PubMed ID: 15585882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide.
    Janssen EM; van Oosterhout AJ; van Rensen AJ; van Eden W; Nijkamp FP; Wauben MH
    J Immunol; 2000 Jan; 164(2):580-8. PubMed ID: 10623798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28.
    Ryan M; McCarthy L; Rappuoli R; Mahon BP; Mills KH
    Int Immunol; 1998 May; 10(5):651-62. PubMed ID: 9645613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction and inhibition of the Th2 phenotype spread: implications for childhood asthma.
    Hayashi T; Gong X; Rossetto C; Shen C; Takabayashi K; Redecke V; Spiegelberg H; Broide D; Raz E
    J Immunol; 2005 May; 174(9):5864-73. PubMed ID: 15843591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors.
    Horng T; Barton GM; Flavell RA; Medzhitov R
    Nature; 2002 Nov; 420(6913):329-33. PubMed ID: 12447442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos.
    Agrawal S; Agrawal A; Doughty B; Gerwitz A; Blenis J; Van Dyke T; Pulendran B
    J Immunol; 2003 Nov; 171(10):4984-9. PubMed ID: 14607893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toll-like receptor 2 ligands as adjuvants for human Th1 responses.
    Sieling PA; Chung W; Duong BT; Godowski PJ; Modlin RL
    J Immunol; 2003 Jan; 170(1):194-200. PubMed ID: 12496400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen.
    Eisenbarth SC; Piggott DA; Huleatt JW; Visintin I; Herrick CA; Bottomly K
    J Exp Med; 2002 Dec; 196(12):1645-51. PubMed ID: 12486107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TLR3-, TLR7-, and TLR9-mediated production of proinflammatory cytokines and chemokines from murine connective tissue type skin-derived mast cells but not from bone marrow-derived mast cells.
    Matsushima H; Yamada N; Matsue H; Shimada S
    J Immunol; 2004 Jul; 173(1):531-41. PubMed ID: 15210814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutting edge: distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells.
    McCurdy JD; Olynych TJ; Maher LH; Marshall JS
    J Immunol; 2003 Feb; 170(4):1625-9. PubMed ID: 12574323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-12p70-dependent Th1 induction by human B cells requires combined activation with CD40 ligand and CpG DNA.
    Wagner M; Poeck H; Jahrsdoerfer B; Rothenfusser S; Prell D; Bohle B; Tuma E; Giese T; Ellwart JW; Endres S; Hartmann G
    J Immunol; 2004 Jan; 172(2):954-63. PubMed ID: 14707068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10.
    Kaesler S; Volz T; Skabytska Y; Köberle M; Hein U; Chen KM; Guenova E; Wölbing F; Röcken M; Biedermann T
    J Allergy Clin Immunol; 2014 Jul; 134(1):92-9. PubMed ID: 24698321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutting edge: impaired Toll-like receptor expression and function in aging.
    Renshaw M; Rockwell J; Engleman C; Gewirtz A; Katz J; Sambhara S
    J Immunol; 2002 Nov; 169(9):4697-701. PubMed ID: 12391175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.
    Querec T; Bennouna S; Alkan S; Laouar Y; Gorden K; Flavell R; Akira S; Ahmed R; Pulendran B
    J Exp Med; 2006 Feb; 203(2):413-24. PubMed ID: 16461338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity.
    Kim WS; Kim H; Kwon KW; Im SH; Lee BR; Ha SJ; Shin SJ
    Oncotarget; 2016 Jun; 7(23):33765-82. PubMed ID: 27172902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.